The WHO's July 4 situation report confirmed at least 506 deaths and 1,561 confirmed cases of Ebola in the Democratic Republic of Congo since the epidemic was officially declared on May 15, 2026. Congolese health authorities published matching figures on July 5, per CGTN Africa, corroborating the WHO count independently.

This is Congo's 17th Ebola epidemic, and its speed is without precedent. The WHO stated that the first month alone was the worst on record for any Ebola outbreak in DRC. The virus is the Bundibugyo strain (BDBV)—a distinct type within the Orthoebolavirus family—for which no licensed vaccine and no approved treatment currently exist. This absence changes outbreak response fundamentally. In past DRC Ebola episodes, health teams could use ring vaccination (targeted immunization of people around confirmed cases) or antibody cocktails to contain spread. Neither option is available this time.

The Geography of Risk

The outbreak started in Mongbwalu, Ituri province. The DRC Ministry of Health declared three health zones affected from the outset: Rwampara, Mongwalu, and Bunia. The Institut National de Recherche Biomédicale (INRB) confirmed 8 positive cases from 13 samples tested on May 14, triggering that declaration. Ituri's case-fatality rate now stands at 50.7 percent—meaning just over half of confirmed cases have resulted in death.

North Kivu province reports an even higher rate: 57.4 percent, a figure Congolese officials have called "worrying." North Kivu faces particular challenges for outbreak control. Years of armed conflict have eroded health infrastructure, disrupted the systems used to track disease spread, and damaged communities' willingness to trust government health efforts. A fatality rate above 50 percent in active conflict zones typically reflects a combination of patients arriving at clinics only in late-stage illness and incomplete identification of cases.

Spread beyond Congo's borders has been limited but not stopped. Uganda confirmed two imported cases on May 15 and 16. As of the most recent reporting, Uganda has recorded two deaths and 20 confirmed cases—a substantially lower toll, but enough to put Uganda's Ministry of Health on heightened alert. The WHO declared a Public Health Emergency of International Concern (PHEIC) on May 16, 2026—within 24 hours of Uganda's first confirmed import—reflecting the cross-border dimension as much as the case count in Congo.

The Pace of Escalation

The numbers show an alarming trajectory. By May 21, the WHO's early reports recorded only 85 confirmed cases. By July 1—six weeks later—the count stood at 1,460 confirmed cases and 452 deaths. The July 4 report moved confirmed cases to 1,561 and deaths to 506. That is roughly 100 additional confirmed cases and 54 additional deaths in just three days—a rate of transmission showing no signs of slowing.

Without approved treatments or vaccines, response options have narrowed. A clinical trial testing two experimental therapeutics for Bundibugyo began around July 2, according to Al Jazeera. The WHO granted Emergency Use Listing for the first diagnostic test designed specifically for BDBV—a meaningful operational advantage, since faster, strain-specific tests shorten the window between symptom appearance and patient isolation. Africa CDC and WHO jointly launched a Continental Preparedness and Response Plan in early June covering through November 2026. Health ministers from DRC, Uganda, and South Sudan met in Kampala on May 23 to coordinate a regional response framework.

These steps carry real weight. But a clinical trial that started on July 2 will not produce results fast enough to change the current trajectory. Even under emergency-use protocols, therapeutics require manufacturing capacity, cold-chain logistics to keep them viable, and trained personnel to administer them safely—all constrained in the affected zones.

The deeper context matters for how international partners direct resources. The previous DRC Ebola outbreak ended in December 2025—less than six months before this one began. Back-to-back epidemics exhaust health workers, stretch surveillance systems to their limits, and drain national medical stockpiles. An outbreak involving a pathogen with no existing medical countermeasures, spreading through an active conflict zone, carrying a fatality rate above 50 percent in its most affected province—this places the response in a different operational category than any DRC Ebola outbreak of the past decade. The numbers are likely to climb further. The epidemiological curve has not bent downward.